HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension. According to GlobalData, Phase II drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HUC-3443 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HUC-3443 overview
HUC3-443 is under development for the treatment of essential hypertension and hypercholesterolemia. It is administered through oral route.
Huons overview
Huons, formerly Kwang Myung Pharmaceutical, develops and manufactures pharmaceutical drugs and medical device solutions. The company offers circulatory system products, metabolic products, anti-inflammatory products, musculoskeletal system products, and digestive system products. It also offers antihistamines, respiratory systems, antibiotics, well-being products, urogenital system products, and others. Huons provides products in various compositions including oral solid form, injection, medical devices, eye drops, and bioproducts. The company exports products to countries in North America, Europe, and Asia. It operates with manufacturing, and research and development facilities in South Korea and China. Huons is headquartered in Seongnam City, Seol, South Korea.
For a complete picture of HUC-3443’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
